Implementation of whole-exome sequencing for pharmacogenomics profiling and exploring its potential clinical utilities

Reference

• Huang SM , TempleR. Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin. Pharmacol. Ther.84(3), 287–294 (2008).
   PubMed Web of Science ®Google Scholar
• Reyner E , LumB , JingJ , KagedalM , WareJA , DickmannLJ. Intrinsic and extrinsic pharmacokinetic variability of small molecule targeted cancer therapy. Clin. Transl. Sci.13(2), 410–418 (2020).
   PubMed Web of Science ®Google Scholar
• Ma Q , LuAY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol. Rev.63(2), 437–459 (2011).
   PubMed Web of Science ®Google Scholar
• Sim SC , KacevskaM , Ingelman-SundbergM. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J.13(1), 1–11 (2013).
   PubMed Web of Science ®Google Scholar
• Li J , BluthMH. Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy. Pharmgenomics Pers. Med.4, 11–33 (2011).
   PubMedGoogle Scholar
• US Food and Drug Administration . Table of pharmacogenomic biomarkers in drug labeling. www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling
   Google Scholar
• Annotation of FDA Label for siponimod and CYP2C9. www.accessdata.fda.gov/drugsatfda_docs/label/2023/209884s015lbl.pdf
   Google Scholar
• El Rouby N , LimaJJ , JohnsonJA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin. Drug Metab. Toxicol.14(4), 447–460 (2018).
   PubMed Web of Science ®Google Scholar
• Stingl J , VivianiR. Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. J. Intern. Med.277(2), 167–177 (2015).
   PubMed Web of Science ®Google Scholar
• Tornio A , BackmanJT. Cytochrome P450 in pharmacogenetics: an update. Adv. Pharmacol.83, 3–32 (2018).
   PubMedGoogle Scholar
• Bienfait K , ChhibberA , MarshallJCet al. Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG). Hum. Genet.141(6), 1165–1173 (2022).
   PubMed Web of Science ®Google Scholar
• Medwid S , KimRB. Implementation of pharmacogenomics: where are we now?Br. J. Clin. Pharmacol. doi: 10.1111/bcp.15591 (2022) .
   PubMed Web of Science ®Google Scholar
• Arbitrio M , SciontiF , DiMartino MTet al. Pharmacogenomics biomarker discovery and validation for translation in clinical practice. Clin. Transl. Sci.14(1), 113–119 (2021).
   PubMed Web of Science ®Google Scholar
• Tafazoli A , VanDer Lee M , SwenJJet al. Development of an extensive workflow for comprehensive clinical pharmacogenomic profiling: lessons from a pilot study on 100 whole exome sequencing data. Pharmacogenomics J.22(5–6), 276–283 (2022).
   PubMed Web of Science ®Google Scholar
• Aboul-Soud MaM , AlzahraniAJ , MahmoudA. Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing. Saudi J. Biol. Sci.28(1), 628–634 (2021).
   PubMed Web of Science ®Google Scholar
• Wang L , SchererSE , BielinskiSJet al. Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: the Mayo-Baylor RIGHT 10K Study. Genet. Med.24(5), 1062–1072 (2022).
   PubMed Web of Science ®Google Scholar
• Lanillos J , CarcajonaM , MaiettaP , AlvarezS , Rodriguez-AntonaC. Clinical pharmacogenetic analysis in 5001 individuals with diagnostic exome sequencing data. NPJ Genom. Med.7(1), 12 (2022).
   PubMed Web of Science ®Google Scholar
• Suwinski P , OngC , LingMHT , PohYM , KhanAM , OngHS. Advancing personalized medicine through the application of whole exome sequencing and big data analytics. Front. Genet.10, 49 (2019).
   PubMed Web of Science ®Google Scholar
• Samuels M , FalkeniusJ , Bar-AdVet al. A phase 1 study of the DNA-PK inhibitor peposertib in combination with radiation therapy with or without cisplatin in patients with advanced head and neck tumors. Int. J. Radiat. Oncol. Biol. Phys.118(3), 743–756 (2023).
   PubMed Web of Science ®Google Scholar
• Cingolani P , Platts, A , Wangleet al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly. 6(2), 80–92 (2012).
   PubMed Web of Science ®Google Scholar
• Cingolani P . SnpSift. [Software] (2012). http://snpeff.sourceforge.net/SnpSift.html
   Google Scholar
• Davydov E V , GoodeD L , SirotaMet al. Identifying a high fraction of the human genome to be under selective constraint using GERP++. PLOS Computational Biology6(12), e1001025 (Year).
   PubMed Web of Science ®Google Scholar
• Schwarz J M , RödelspergerC , SchuelkeM , SeelowD. MutationTaster evaluates disease-causing potential of sequence alterations. Nature Methods7(8), 575–576 (2010).
   PubMed Web of Science ®Google Scholar
• Gong L , Whirl-CarrilloM , KleinTE. PharmGKB, an integrated resource of pharmacogenomic knowledge. Curr. Protoc.1(8), e226 (2021).
   PubMedGoogle Scholar
• McDonagh EM , WassenaarC , DavidSPet al. PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenet. Genomics22(9), 695–708 (2012).
   PubMed Web of Science ®Google Scholar
• Lopacinska-Joergensen J , OliveiraD , PoulsenTS , HoegdallCK , HoegdallEV. Somatic variants in DNA damage response genes in ovarian cancer patients using whole-exome sequencing. Anticancer Res.43(5), 1891–1900 (2023).
   PubMed Web of Science ®Google Scholar
• Wen L , BrittonCJ , GarjeR , DarbroBW , PackiamVT. The emerging role of somatic tumor sequencing in the treatment of urothelial cancer. Asian J. Urol. 8(4), 391–399 (2021).
   PubMed Web of Science ®Google Scholar
• Gray SW , ParkER , NajitaJet al. Oncologists’ and cancer patients’ views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genet. Med.18(10), 1011–1019 (2016).
   PubMed Web of Science ®Google Scholar
• Chua EW , CreeSL , TonKNet al. Cross-comparison of exome analysis, next-generation sequencing of amplicons, and the iPLEX(®) ADME PGx panel for pharmacogenomic profiling. Front. Pharmacol.7, 1 (2016).
   PubMed Web of Science ®Google Scholar
• Taylor C , CrosbyI , YipV , MaguireP , PirmohamedM , TurnerRM. A Review of the Important Role of CYP2D6 in Pharmacogenomics. Genes (Basel)11(11), 1295 (2020).
   PubMed Web of Science ®Google Scholar
• Barbarino JM , Whirl-CarrilloM , AltmanRB , KleinTE. PharmGKB: a worldwide resource for pharmacogenomic information. Wiley Interdiscip. Rev. Syst. Biol. Med.10(4), e1417 (2018).
   PubMed Web of Science ®Google Scholar
• Donoghue MTA , SchramAM , HymanDM , TaylorBS. Discovery through clinical sequencing in oncology. Nat. Cancer1(8), 774–783 (2020).
   PubMedGoogle Scholar